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Abstract  
Purpose: To compare non-target tissue (including left-anterior-descending coronary-artery (LAD)) 
dosimetry of whole (WBI) and partial-breast irradiation (PBI) planned in prone versus supine 
positions. 
Methods and materials: Sixty-five post-lumpectomy breast cancer patients underwent CT-
imaging supine and prone. On each dataset, whole-breast clinical-target-volume (CTV) was 
defined using wire and partial-breast CTV as tumour-bed+15mm.  Heart and LAD were outlined in 
left-breast-affected patients (n=30), and ipsilateral lung and chest-wall in all patients. Tangential-
field WBI and PBI plans were generated for each position. Mean LAD, heart, and ipsilateral lung 
doses (NTDmean), maximum LAD (LADmax) doses, and chest-wall V50Gy were compared. 
Results: 260 plans were generated. Prone positioning reduced heart and LAD doses in 19/30 WBI 
cases (mean reduction in LAD-NTDmean=7.5Gy) and 7/30 PBI cases (mean reduction in LADmax 
=27.6Gy). However, prone positioning increased cardiac doses in 8/30 WBI (mean increase in 
LAD-NTDmean=8.4Gy) and 19/30 PBI cases (mean increase in LADmax=23.7Gy). WB-
CTV>1000cm3 was associated with improved cardiac dosimetry in the prone position for WBI 
(p=0.04) and PBI (p=0.02). Prone positioning reduced ipsilateral-lung NTDmean in 65/65 WBI and 
61/65 PBI cases, and chest-wall V50Gy in all WBI cases. PBI reduced normal-tissue doses 
compared to WBI in all cases, regardless of treatment position. 
Conclusions: In the context of tangential-field WBI and PBI, prone positioning is likely to benefit 
left-breast-affected women of cup-size ≥D, and most right-breast-affected women, but to be 
detrimental in left-breast-affected women of smaller cup size. PBI reliably reduces normal-tissue 
doses compared to WBI such that eligible women should be encouraged to participate in PBI 
studies. 
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Introduction 
Whole-breast irradiation (WBI) following breast-conserving surgery (BCS) improves local control 
and survival from breast cancer but increases non-breast-cancer-related deaths by 1% at 15 years 
(1). The majority of these deaths are cardiovascular in origin (2) and irradiation of the left-anterior-
descending coronary-artery (LAD) is implicated in pathogenesis (3-5). Irradiation of lung, chest-
wall and other tissues also contributes to late mortality and morbidity (1, 2). Improvements in 
radiotherapy techniques have resulted in reduced normal-tissue doses (6), correlating with 
reduced non-breast-cancer-related mortality (2). Nonetheless doses to the heart, LAD and lung 
from current standard supine WBI remain significant (7).  
Methods by which normal-tissue doses could be decreased include optimization of patient 
positioning and use of partial-breast irradiation (PBI). Prone positioning for WBI improves dose 
homogeneity within breast-tissue (8, 9), reduces lung doses (10-12), and reduces wedge 
requirements with consequent reduction of scattered dose, particularly in women of larger cup-size 
(10). However, reports comparing cardiac dosimetry from supine versus prone WBI are conflicting. 
One study using IMRT (13) reported that prone positioning reduced within-field heart volume in 
85% of women. However, studies using conventional tangential-field arrangements have failed to 
show an overall benefit of prone positioning on cardiac dosimetry (11, 14). Furthermore, a study 
comparing distances between anterior pericardium and chest-wall on supine CT-images and prone 
MRI (15) found prone positioning to systematically displace supero-lateral aspects of heart-tissue 
closer to chest-wall, such that prone positioning might be detrimental where target tissues include 
chest-wall and/or deeply-lying breast tissue. Thus far, LAD doses from prone positioning have not 
been documented.  
PBI could also reduce normal-tissue doses by restricting higher radiation doses to the volume of 
breast tissue at highest risk of tumour relapse (16). The combination of prone positioning and PBI 
is particularly attractive in terms of reducing normal-tissue toxicity. A dosimetric comparison of 
accelerated PBI techniques (14) found that brachytherapy & prone tomotherapy resulted in least 
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dose to lung and non-target ipsilateral breast tissue (compared with supine 3D-conformal-RT and 
tomotherapy). However, heart doses again varied between patients, prone tomotherapy benefiting 
only women with larger breasts and/or lesions further from chest-wall. 
Cardiac and, in particular, LAD dosimetry from prone WBI and PBI require further evaluation 
before prone positioning can be adopted into routine practice. As the majority of centres worldwide 
continue to use conventional tangential-field arrangements, this study prospectively evaluates non-
target tissue exposure from WBI and PBI planned conventionally in supine and prone positions 
using within-patient comparison. The resulting four-way comparison of prone and supine, WBI and 
PBI aims to clarify optimal approaches to reducing normal-tissue exposure applicable to the 
majority of current practices.  
Methods and materials 
This study was approved by the Royal Marsden Committee for Clinical Research and the Regional 
Ethics Committee. All women had undergone BCS for unifocal T1-2 G1-3 invasive-ductal 
carcinoma or high-grade ductal-carcinoma-in-situ, at which time titanium-clips were placed in the 
tumour-bed (TB) according to a UK protocol (17).  
Patient positioning and image acquisition 
Patients underwent non-contrast CT-imaging (slice-thickness 1.5mm, C6 to below diaphragm) in 
the standard supine position at which time radio-opaque wire was placed at the palpable edge of 
breast-tissue circumferentially. Patients were repositioned and CT-imaged prone using an in-
house-designed platform, with an aperture through which index-breast could fall away from chest-
wall [Figure 1]. Radio-opaque wire remained in-situ for prone CT-imaging.  
Target and non-target tissue delineation 
Whole-breast (WB) clinical-target-volume (CTV) was defined using wire plus any additional breast-
tissue visualized on CT, limited by 5mm from skin and chest-wall/lung interfaces. Partial-breast 
CTV was defined as TB (clips plus seroma and/or architectural distortion) expanded by 15mm in 3-
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D (limited circumferentially by WB-CTV). Planning-target-volumes (PTV) were generated by 
addition of 3-D 10mm margins to CTV, limited by 5mm from skin.  
Heart and LAD were defined according to published criteria (6). Where LAD was difficult to 
visualise, its location was inferred from the course of the anterior-interventricular groove (6). 
Consistent with previous practice, an 10mm axial margin was added to the LAD to allow for 
delineation-uncertainty, respiratory-motion and cardiac-motion (7). Ipsilateral-lung was outlined 
using an autocontour tool (edited to exclude major airways). Chest-wall was defined as ipsilateral 
ribcage and intercostal musculature. 
Radiotherapy-planning 
For each position, standard opposing tangential-fields were employed such that for WBI, ≥90% of 
WB-CTV was encompassed by the 95%-isodose and, for PBI, ≥95% of partial-breast CTV was 
encompassed by the 95%-isodose (according to UK National-Cancer-Research-Institute Intensity-
Modulated Partial Organ Radiotherapy (IMPORT) study criteria (18)). Plans fulfilled ICRU dose-
homogeneity criteria (19). Dose-distributions were reviewed in 3D and using dose-volume-
histogram (DVH) data. 50Gy in 25 fractions over 5 weeks (6-10MV photons) was prescribed to the 
100% isodose. MLC leaves were used as required to reduce cardiac doses whilst maintaining 
satisfactory coverage of WB and PB-CTVs as defined above. 
Analysis 
NTDmean (a biologically-weighted mean of dose to normal-tissue normalised to 2Gy fractions (20)) 
was calculated for heart, LAD, and lung. Maximum-dose to LAD (LADmax) was read from DVH data. 
The volume of chest-wall receiving 50Gy (V50Gy) was calculated.  
Differences between heart, LAD and lung-NTDmean, LADmax, and chest-wall V50Gy for supine versus 
prone WBI, supine versus prone PBI, and supine WBI versus PBI plans were calculated for each 
patient and compared using the paired t-test or Wilcoxon signed-rank test, as appropriate. Lung 
and chest-wall doses were compared in all patients. Cardiac doses were compared for left-breast-
affected patients only (as a population and by individual patient). Individual-patient cardiac data 
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were pooled by WB-CTV into tertiles (≤500cm3, 501-1000cm3, >1000cm3) and the likelihood of 
benefit from prone positioning compared between tertiles using analysis-of-variance.  
Results 
65 women were recruited (30 left-sided: 35 right-sided BC). Mean age was 57 years (range 34-79 
years). Self-reported cup-sizes and WB-CTVs are illustrated in figure 2. There was no difference 
between WB-CTVs delineated in supine and prone positions (p=0.15). Satisfactory coverage of 
target-volumes was achieved in 100% of plans.  
Cardiac dosimetry 
Heart and LAD doses for the patients with left BC (30 cases, 120 plans) are summarized in table 1 
and figure 3. Overall, for the population of left-breast-affected women, there was no significant 
difference in cardiac parameters between prone and supine positions for either WBI or PBI.  
Comparing doses within patients, for WBI prone positioning was advantageous in 19/30 patients 
but disadvantageous in 8/30 patients. The magnitude of the difference between LAD-NTDmean 
doses was similar whether prone positioning improved or worsened dosimetry [table 2]. In 3/30 
patients, prone positioning increased LAD-NTDmean but decreased LADmax. If heart-NTDmean had 
been the only comparator, 20/30 would have been judged to benefit from prone and 10/30 from 
supine positioning.  
For PBI, prone positioning was advantageous in 7/30 patients, and disadvantageous in 19/30 
patients. The magnitude of the difference between LADmax doses was similar whether prone 
positioning improved or worsened dosimetry. In 4/30 cases, parameters failed to agree on optimal 
position. If heart NTDmean had been the only comparator, 13/30 patients would have been judged to 
benefit from prone and 17/30 from supine positioning. 
Across all 60 WBI-plans for left-breast-affected cases, LADmax was high (≥29.9Gy) irrespective of 
treatment position. The mean difference in LADmax for prone versus supine WBI was 4.5±2.5Gy. 
There was greater inter-patient variability in LAD NTDmean (mean difference in prone versus supine 
LAD-NTDmean=7.7±2.3Gy3). Conversely, across all 60 PBI plans, LAD-NTDmean was low (mean 
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LAD-NTDmean =2.8±2.5Gy3) with a mean difference in prone versus supine LAD-NTDmean of 
2.6±1.2Gy3. There was greater inter-patient variability in LADmax (mean difference in prone versus 
supine LADmax =25.7±8.5Gy). There was a correlation between heart- and LAD-NTDmean (R= 0.80 
for WBI, p=0.01; R=0.67 for PBI, p=0.01), and between heart-NTDmean and LADmax (R= 0.44 for 
WBI, p=0.01; R=0.59 for PBI, p=0.01). 
Analysing results by volumetric-tertile, for WBI there was a significant benefit of prone positioning 
on cardiac doses for women with breast volumes >1000cm3 (p=0.04) [figure 4]. All women of D-cup 
or above benefited from the prone position with the exception of one patient (G cup) whose TB 
was in the axillary-tail. In the context of PBI, there was a significant benefit of prone positioning on 
LADmax doses (p=0.02) but not on heart- (p=0.09) or LAD-NTDmean (p=0.14) doses for women with 
breast-volumes >1000cm3. A breast volume of ≤1000cm3 was significantly associated with a 
benefit from supine positioning in the context of both WBI and PBI.  
Figure 5 demonstrates that in both small- and large-breasted women, heart-tissue moves anteriorly 
in relation to chest-wall. However, the larger breast is pulled further anteriorly than the smaller 
breast owing to the greater weight of breast-tissue such that shallower tangents can be placed 
thereby sparing a greater volume of normal-tissue.  
Cardiac doses were significantly lower for PBI as compared to WBI (p<0.001). Mean reductions in 
heart-NTDmean were 0.7±0.1Gy3 (supine) and 0.5±0.1Gy3 (prone). Mean reductions in LAD-NTDmean 
were 9.4±0.2Gy3 (supine) and 6.1±1.5Gy3 (prone). Mean reductions in LADmax were 22.7±6.2Gy 
(supine) and 11.9±5.4Gy (prone).  
Lung and chest-wall dosimetry 
Ipsilateral-lung NTDmean doses (65 cases, 260 plans) are summarised in table 1 and figure 3d. 
Prone, as compared to supine, positioning significantly reduced ipsilateral-lung NTDmean in 65/65 
WBI cases (mean reduction=3.5±0.5Gy3 (p<0.001)), and 61/65 PBI cases (mean reduction= 
1.1±0.2Gy3(p<0.001). In 4/65 PBI cases, ipsilateral-lung-NTDmean was similar in both positions 
because TBs were located at the lateral edge of breast-tissue such that PB-CTV coverage would 
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have been compromised by shallower tangents in the prone position. Ipsilateral-lung NTDmean was 
significantly lower for PBI as compared to WBI (mean reduction=2.9±0.3Gy3 (supine) and 
0.4±0.1Gy3 (prone)(p<0.001)).  
Prone positioning significantly reduced chest-wall V50Gy for WBI only (table 1, figure 3e). Use of 
supine PBI, compared to WBI, reduced chest-wall V50Gy by 17±7cm3 (p<0.001). There was no 
difference between chest-wall V50Gy for prone PBI versus WBI (p=0.08). 
Discussion 
This study aimed to compare normal-tissue (including left-anterior-descending coronary-artery 
(LAD)) dosimetry from conventional tangential-field whole- and partial-breast radiotherapy planned 
in prone versus supine positions.  
Cardiac dosimetry 
We found the effects of prone positioning upon both heart and LAD doses to be variable between 
patients, consistent with previous studies (10, 14). Around two-thirds of patients planned for WBI 
benefited from prone positioning, with mean improvements in heart-NTDmean, LAD-NTDmean and 
LADmax of 0.4Gy, 7.0Gy and 4.9Gy respectively. However, in a third of patients, prone positioning 
would have increased cardiac doses to a similar extent (table 2). Only a quarter of patients 
planned for PBI would have benefited from prone positioning, with mean improvements in heart-
NTDmean, LAD-NTDmean and LADmax of 0.2Gy, 2.1Gy, and 27.6Gy respectively. In two-thirds of PBI 
cases, prone positioning would have increased cardiac doses to a similar extent (table 2).  
We found a significant benefit of prone positioning upon heart/LAD doses for women of WB-
CTV>1000cm3 (equivalent to UK cup size ≥D) for both WBI and PBI, consistent with previous work 
reporting a trend towards a significant benefit of prone positioning upon heart dose in women of 
breast cup-size ≥E (11). Our findings are also consistent with work reporting that heart-tissue 
moves towards chest-wall in patients positioned prone (15). Only patients in whom breast-tissue 
falls anteriorly in relation to chest-wall in the prone position (such that shallower tangents can be 
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placed) are likely to gain from prone treatment. Otherwise, where smaller breasts are not pulled 
anteriorly, tangents are likely to encompass more cardiac tissue in the prone position.  
Not all patients of large breast size in our study had better cardiac dosimetry in the prone position. 
One patient (cup size G) had a tumour-bed in the axillary tail which could not be encompassed by 
WBI-tangents without increasing their depth and therefore normal-tissue doses. There may be 
other predictive factors including heart-size, chest-wall breadth and curvature that our study is 
underpowered to detect.  
The proportion of women benefitting from prone positioning in our study differed from interim 
reports of the largest ongoing comparative study of prone versus supine WBI, which suggest that 
prone positioning reduces in-field heart volume in the majority (85%) of left-sided BC patients 
(n=200)(13). Discrepancies between results could be due to use of volumetric rather than 
dosimetric comparators and/or to use of IMRT rather than conventional tangential-fields. Using 
IMRT, an in-field heart volume of 0cm3 is likely to be achievable in a proportion of patients in both 
supine and prone positions. In this case, the effect of prone positioning upon heart is assumed to 
be neutral but the prone position might still be judged “optimal” based on reduced in-field lung 
volume compared to the supine position. This approach does not however detect differences in 
lower-dose irradiation of cardiac tissues thereby overestimating the clinical benefits of prone 
positioning in comparison to our study. Our additional use of LAD-dosimetry to discern optimal 
treatment position might also have lead to differing results. Although heart- and LAD-NTDmean 
correlated reasonably well, there was disagreement between heart and LAD doses over optimal 
treatment position in 7/60 plans. Had heart NTDmean been the only comparator, 20/30 and 13/30 
patients would have benefited from prone treatment in the context of WBI and PBI respectively. 
Another source of discrepancies could be the method by which WB-CTV is defined. Clinicians’ 
decisions on where to place the posterior RT-field border in order to achieve target-volume 
coverage will significantly impact upon doses to tissues close to chest-wall. Our study used a 
method of WB-CTV definition agreed to be more representative of the true volume than standard 
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anatomical landmarks (21). Wire-delineated breast tissue shifts anteriorly in the prone position but 
is consistently included as WB-CTV. Our WB-CTVs were comparable between positions with no 
significant difference in percentage volume covered. Additionally, all of our cases had titanium-clip-
defined TB volumes, without which, coverage of PB-CTV at depth cannot be ensured (22). 
The clinical impact of differences in cardiac doses of the magnitude described above is difficult to 
quantify as radiation parameters determining excess cardiovascular disease (CVD) risk are poorly 
understood. Gagliardi (23) used the relative-seriality model to quantitatively describe the dose-
response relationship for excess cardiac mortality and found a low dependence of this endpoint 
upon irradiated-heart-volume, concluding that cardiac mortality is more likely to be reduced by 
decreasing dose than by restricting irradiated volume. Borger et al (24) also found no relationship 
between maximum heart distance (MHD) (a correlate of irradiated-heart-volume) and risk of CVD 
but reported that, even where MHD=0mm, more cardiotoxic effects occurred following left-sided as 
compared to right-sided-RT suggesting that differences in doses <25Gy may be important. Other 
data supporting the hypothesis that low-dose radiation increases CVD risk come from atomic-
bomb survivors (4Gy single exposure) (25), patients treated with RT for peptic-ulcer disease (mean 
heart dose 1.6-3.9Gy) (26), patients treated with para-aortic irradiation for testicular cancer (~1Gy 
scattered heart dose) (27) and radiation workers (28). Cardiac variables which encompass 
volumes of cardiac tissue irradiated to low doses such as heart-NTDmean have shown a strong 
correlation with mortality (29). Optimal positioning in our study decreased mean heart-NTDmean 
from ~1.2 to ~0.8Gy3 for WBI, and from ~0.5 to ~0.3Gy3 for PBI. Based on the evidence above, the 
risks of low-dose cardiac irradiation are not negligible. However, the dose-effect relationship at 
these dose-levels is difficult to define and the clinical consequences of such small differences 
unquantifiable.  
Meanwhile, other studies suggest that LAD dose is the most relevant exposure variable (3-5). 
Retrospective review of patients irradiated between 1977-95 found a significantly higher 
prevalence of cardiac stress-test abnormalities amongst left- versus right-side-irradiated patients, 
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70% of which were in LAD territory (3) CHECK Others correlate a fall in mean LAD doses from 
breast RT over the last 30 years (6, 7) with a decrease in CVD over the same period (2). 
Furthermore, it may be that Gagliardi’s finding of a low dependence of cardiac mortality upon 
irradiated-heart-volume (23) relates to the fact that the LAD is likely to remain within the high-dose 
volume from a tangential-field arrangement even at low irradiated-heart-volumes. Optimal 
positioning in our study decreased mean LAD-NTDmean from ~14Gy to 6Gy for WBI, and from ~4Gy 
to 1.5Gy for PBI. Reductions in dose of these magnitudes could be associated with a significant 
reduction in CVD (7). As atherosclerosis anywhere along the LAD could cause CVD, LADmax is a 
relevant additional variable. Optimal positioning in our study decreased mean LADmax from ~49Gy 
to 45Gy for WBI, and from 42Gy to 15Gy for PBI. The latter could be particularly significant 
depending partly upon the threshold dose for atherosclerosis, Gagliardi’s work suggesting that the 
risk of cardiac mortality rises steeply above doses of around 20Gy regardless of the volume 
irradiated (23). Whether dosimetric differences of these magnitudes continue to be relevant in the 
context of 5mm set-up errors and physiological changes in heart and intra-thoracic volume with 
respiration (each of which may cause interfraction variations in normal-tissue doses) remains to be 
determined.  
Lung and chest-wall dosimetry 
Our study confirms previous reports (10-12) that prone positioning reduces mean lung doses for 
both WBI and PBI and furthermore demonstrates that benefits are applicable to women of all cup-
sizes. The main threat of death in relation to irradiation of lung-tissue is from low-dose stochastic 
effects rather than from high-dose deterministic effects, the relative-risk of death from second-
primary lung cancer ranging from 1.5 to 2.8 at 15 years (30, 31), with odds ratios of up to 37.6 
reported in smokers (32). Data on lung-cancer deaths in ~9000 women irradiated in 1935-1971 
(30) suggest a dose-response relationship with an incremental RR of 0.2 per Gy to ipsilateral-lung 
(equating to 9 cases of RT-induced lung cancer/ year/10,000 women receiving a lung dose of 
10Gy and living to 10 years). The SEER registry cohort demonstrates a similar relationship 
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between mean lung dose and risk of second-primary lung-cancer (2) in women irradiated in 1973-
2001. Our mean lung-NTDmean for supine WBI was 3.7Gy. Prone positioning reduced this to 0.3Gy. 
Based on evidence above, this reduction in dose might prevent around 3 lung cancers/year/10000 
women living to 10 years post-RT. The effect may be larger however in women who smoke, in 
whom prone treatment might be particularly beneficial. 
The START trial suggests that 40% of women experience chest-wall discomfort at 10 years post-
RT (33), whilst the incidence of rib-fracture following WBI is reported to be 0.3-2.2% (34, 35). A 
recent study of external-beam-accelerated-PBI found the incidence of chest-wall pain and rib 
fracture to relate to the volume of chest-wall receiving 35Gy or more (based on 38.5Gy/10 fractions 
5 days (36)). This is equivalent to around 48Gy in 2Gy fractions and is in keeping with tolerance 
doses published by Emami (37) (TD5/5 ribcage ~50Gy). Therefore chest-wall V50Gy could be 
considered a reasonable parameter by which to compare radiotherapeutic approaches in terms of 
late chest-wall discomfort. Prone positioning significantly reduces chest-wall V50Gy in WBI and 
therefore warrants consideration as a technique by which chest-wall morbidity might be reduced.  
The future of prone breast RT 
In departments where conventional tangential-field WBI is standard, prone positioning is likely to 
benefit most left-breast-affected women of cup size ≥D, and nearly all right-breast-affected women. 
A current priority is to establish whether or not the position is reproducible in order that dosimetric 
benefits can be realized. In the context of tangential-field PBI, prone positioning benefited fewer 
left-breast-affected women but still reduced the LADmax by over 20Gy in many large-breasted 
women. Further work in this setting might be helpful in establishing predictive factors for deciding 
optimal treatment position in left-breast-affected women. For right-breast-affected women, 
reductions in lung and chest wall doses are small and a change of treatment technique may not 
therefore be warranted. Based on our results, prone positioning for either WBI or PBI is not 
recommended in left-breast-affected women of cup-size<C as cardiac doses may be significantly 
increased in comparison to supine treatment. 
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PBI versus WBI 
The normal-tissue dosimetric advantages of PBI have been assumed but not proven. Indeed a 
recent study reported that 3D-conformal PBI increased the volume of lung exposed to low-dose 
radiation whilst decreasing the volume of tissue exposed to higher-dose radiation (38). We found 
that supine PBI reduced mean heart-NTDmean (by 0.6Gy), mean LAD-NTDmean (9Gy), mean LADmax 
(23Gy), mean ipsilateral-lung-NTDmean (3Gy) and mean chest-wall V50Gy (17cm3) compared to 
supine WBI. With dose-sparing of this magnitude, it seems likely that PBI will reduce long-term 
cardiovascular side-effects of breast RT, reduce second-primary lung malignancies by around 2 
lung cancers/year/10000 women at 10 years post-RT, and reduce the incidence of late chest-wall 
discomfort. PBI should be considered the optimal strategy for reducing late morbidity of breast RT 
but is currently only available in trials for which many women are ineligible. Prone positioning still 
has a role in reducing normal-tissue toxicity in women requiring adjuvant WBI.  
Conclusions 
In the context of tangential-field WBI and PBI, prone positioning is likely to benefit left-breast-
affected women of cup-size ≥D, and most right-breast-affected women, but to be detrimental in 
left-breast-affected women of smaller cup size. PBI reliably reduces normal-tissue doses 
compared to WBI such that eligible women should be encouraged to participate in PBI studies. 
Prone breast dosimetry    Kirby page 14
References  
1. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent 
of surgery for early breast cancer on local recurrence and 15-year survival: an overview of 
the randomised trials. Lancet 2005;366:2087-2106. 
2. Darby SC, McGale P, Taylor CW, et al. Long-term mortality from heart disease and lung 
cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 
women in US SEER cancer registries. Lancet Oncol 2005;6:557-565. 
3. Correa CR, Das IJ, Litt HI, et al. Association between tangential beam treatment parameters 
and cardiac abnormalities after definitive radiation treatment for left-sided breast cancer. Int 
J Radiat Oncol Biol Phys 2008;72:508-516. 
4. Storey MR, Munden R, Strom EA, et al. Coronary artery dosimetry in intact left breast 
irradiation. Cancer J 2001;7:492-497. 
5. Lind PA, Pagnanelli R, Marks LB, et al. Myocardial perfusion changes in patients irradiated 
for left-sided breast cancer and correlation with coronary artery distribution. Int J Radiat 
Oncol Biol Phys 2003;55:914-920. 
6. Taylor CW, Nisbet A, McGale P, et al. Cardiac exposures in breast cancer radiotherapy: 
1950s-1990s. Int J Radiat Oncol Biol Phys 2007;69:1484-1495. 
7. Taylor CW, Povall JM, McGale P, et al. Cardiac dose from tangential breast cancer 
radiotherapy in the year 2006. Int J Radiat Oncol Biol Phys 2008;72:501-507. 
8. Merchant TE, McCormick B. Prone position breast irradiation. Int J Radiat Oncol Biol Phys 
1994;30:197-203. 
9. Grann A, McCormick B, Chabner ES, et al. Prone breast radiotherapy in early-stage breast 
cancer: a preliminary analysis. Int J Radiat Oncol Biol Phys 2000;47:319-325. 
10. Griem KL, Fetherston P, Kuznetsova M, et al. Three-dimensional photon dosimetry: a 
comparison of treatment of the intact breast in the supine and prone position. Int J Radiat 
Oncol Biol Phys 2003;57:891-899. 
Prone breast dosimetry    Kirby page 15
11. Buijsen J, Jager JJ, Bovendeerd J, et al. Prone breast irradiation for pendulous breasts. 
Radiother Oncol 2007;82:337-340. 
12. DeWyngaert JK, Jozsef G, Mitchell J, et al. Accelerated intensity-modulated radiotherapy to 
breast in prone position: dosimetric results. Int J Radiat Oncol Biol Phys 2007;68:1251-
1259. 
13. Formenti S, Lymberis S, Parhar  P, Fenton-Kerimian M, Magnolfi C, Wen B, Chang J, 
DeWyngaert J. Results of NYU 05-181: A prospective trial to determine optimal position 
(prone versus supine) for breast radiotherapy. Int J Radiat Biol 2009;75:S203-S204. 
14. Patel RR, Becker SJ, Das RK, et al. A dosimetric comparison of accelerated partial breast 
irradiation techniques: multicatheter interstitial brachytherapy, three-dimensional conformal 
radiotherapy, and supine versus prone helical tomotherapy. Int J Radiat Oncol Biol Phys 
2007;68:935-942. 
15. Chino JP, Marks LB. Prone positioning causes the heart to be displaced anteriorly within the 
thorax: implications for breast cancer treatment. Int J Radiat Oncol Biol Phys 2008;70:916-
920. 
16. Smith TE, Lee D, Turner BC, et al. True recurrence vs. new primary ipsilateral breast tumor 
relapse: an analysis of clinical and pathologic differences and their implications in natural 
history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys 
2000;48:1281-1289. 
17. Coles CE, Wilson CB, Cumming J, et al. Titanium clip placement to allow accurate tumour 
bed localisation following breast conserving surgery: audit on behalf of the IMPORT Trial 
Management Group. Eur J Surg Oncol 2009;35:578-582. 
18. Yarnold, J, Coles, C. On behalf of the IMPORT-Low Trial Management Group.  Intensity-
Modulated and Partial Organ Radiotherapy. Randomised trial testing intensity-modulated 
and partial organ radiotherapy following breast conservation surgery for early breast cancer. 
Trial Protocol, version 4. Institute of Cancer Research, Sutton, UK. p.1-74. 
Prone breast dosimetry    Kirby page 16
19. ICRU Report 62. Prescribing, Recording and Reporting Photon Beam Therapy (Supplement 
to ICRU Report 50). Maryland:Bethseda; 1999. 
20. Scrimger RA, Tome WA, Olivera GH, et al. Reduction in radiation dose to lung and other 
normal tissues using helical tomotherapy to treat lung cancer, in comparison to conventional 
field arrangements. Am J Clin Oncol 2003;26:70-78. 
21. Valdagni R, Italia C, Montanaro P, et al. Clinical target volume localization using 
conventional methods (anatomy and palpation) and ultrasonography in early breast cancer 
post-operative external irradiation. Radiother Oncol 1997;42:231-237. 
22. Algan O, Fowble B, McNeeley S, et al. Use of the prone position in radiation treatment for 
women with early stage breast cancer. Int J Radiat Oncol Biol Phys 1998;40:1137-1140. 
23. Gagliardi G, Lax I, Ottolenghi A, et al. Long-term cardiac mortality after radiotherapy of 
breast cancer--application of the relative seriality model. Br J Radiol 1996;69:839-846. 
24. Borger JH, Hooning MJ, Boersma LJ, et al. Cardiotoxic effects of tangential breast 
irradiation in early breast cancer patients: the role of irradiated heart volume. Int J Radiat 
Oncol Biol Phys 2007;69:1131-1138. 
25. Preston DL, Shimizu Y, Pierce DA, et al. Studies of mortality of atomic bomb survivors. 
Report 13: Solid cancer and noncancer disease mortality: 1950-1997. Radiat Res 
2003;160:381-407. 
26. Carr ZA, Land CE, Kleinerman RA, et al. Coronary heart disease after radiotherapy for 
peptic ulcer disease. Int J Radiat Oncol Biol Phys 2005;61:842-850. 
27. van den Belt-Dusebout AW, Nuver J, de Wit R, et al. Long-term risk of cardiovascular 
disease in 5-year survivors of testicular cancer. J Clin Oncol 2006;24:467-475. 
28. McGale P, Darby SC. Low doses of ionizing radiation and circulatory diseases: a systematic 
review of the published epidemiological evidence. Radiat Res 2005;163:247-257. 
29. Perman M, Johanson, I, Ohlson, B, Johansson, KA, Karlsson, P. Death from ischaemic 
heart disease 10-19 years after treatment for early breast cancer: a population-based 
Prone breast dosimetry    Kirby page 17
nested case-control study regarding absorbed dose to the heart and 11 anatomical 
substructures of the heart. Radiother Oncol 2008;x:x. 
30. Inskip PD, Stovall M, Flannery JT. Lung cancer risk and radiation dose among women 
treated for breast cancer. J Natl Cancer Inst 1994;86:983-988. 
31. Roychoudhuri R, Evans H, Robinson D, et al. Radiation-induced malignancies following 
radiotherapy for breast cancer. Br J Cancer 2004;91:868-872. 
32. Kaufman EL, Jacobson JS, Hershman DL, et al. Effect of breast cancer radiotherapy and 
cigarette smoking on risk of second primary lung cancer. J Clin Oncol 2008;26:392-398. 
33. Bentzen SM, Agrawal RK, Aird EG, et al. The UK Standardisation of Breast Radiotherapy 
(START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a 
randomised trial. Lancet Oncol 2008;9:331-341. 
34. Pierce SM, Recht A, Lingos TI, et al. Long-term radiation complications following 
conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast 
cancer. Int J Radiat Oncol Biol Phys 1992;23:915-923. 
35. Meric F, Buchholz TA, Mirza NQ, et al. Long-term complications associated with breast-
conservation surgery and radiotherapy. Ann Surg Oncol 2002;9:543-549. 
36. Reeder R, Carter DL, Howell K, et al. Predictors for clinical outcomes after accelerated 
partial breast intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2009;74:92-97. 
37. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int 
J Radiat Oncol Biol Phys 1991;21:109-122. 
38. Jain AK, Vallow LA, Gale AA, et al. Does three-dimensional external beam partial breast 
irradiation spare lung tissue compared with standard whole breast irradiation? Int J Radiat 
Oncol Biol Phys 2009;75:82-88. 
 
 
Prone breast dosimetry    Kirby page 18
Table 1. Mean normal tissue doses (with 95% confidence intervals) 
 Supine 
WBI 
Prone 
WBI 
Difference 
between 
prone & 
supine 
WBI 
p Supine 
PBI 
Prone 
PBI  
Difference 
between 
prone & 
supine 
PBI 
p 
Heart-NTDmean 
(Gy3)  
1.0±0.1  0.9±0.1  0.1±0.2 0.14 0.4±0.1 0.4±0.1 0.1±0.1 0.08 
LAD-NTDmean 
(Gy3)  
11.5±2.3 9.6±1.9 1.9±3.0 0.21 2.1±0.6 3.5±1.1 1.4±1.2 0.02 
LADmax (Gy)  48.6±1.5 46.5±1.6 2.2±2.1 0.04 25.9±6.6 34.5±6.1 8.6±9.2 0.07 
Ipsilateral-lung 
NTDmean (Gy3)  
3.7±0.8 0.3±0.8 3.5±0.5 <0.001 1.4±0.5 0.2±0.1 1.1±0.2 <0.001 
Chest-wall 
V50Gy (cm3) 
20±7 2±1 18±7 <0.001 3±2 1±1 2±2 0.08 
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Table 2: Comparison of cardiac doses according to superiority of patient position for WBI 
and PBI 
 
 
 Supine position better Prone position better 
WBI N=8 N=19 
 Supine Prone Difference p Supine Prone Difference p 
Heart-NTDmean 
(Gy3)  
0.7±0.1 1.1±0.3 0.5±0.2 0.01 1.2±0.2 0.8±0.1 0.4±0.1 <0.001 
LAD-NTDmean 
(Gy3) 
5.1±2.2 13.5±3.2 8.4±2.5 <0.001 14.6±2.4 7.5±2.1 7.0±2.1 <0.001 
LADmax (Gy) 45.1±4.7 49.1±1.8 3.9±3.3 0.05 49.7±0.4 44.9±1.9 4.9±1.7 <0.001 
PBI N=19 N=7 
 Supine Prone Difference p Supine Prone Difference p 
Heart NTDmean 
(Gy3)  
0.3±0.1 0.5±0.1 0.2±0.1  0.002 0.4±0.1 0.3±0.1 0.2±0.1  0.10 
LAD NTDmean 
(Gy3) 
1.7±0.7 4.6±1.4 3.0±1.1  <0.001 3.4±1.4 1.3±0.8 2.1±1.4  0.03 
LADmax (Gy) 19.0±7.6 42.7±3.6 23.7±6.5  <0.001 41.9±5.4 14.3±12.7 27.6±10.5  0.003 
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Figure Captions 
Figure 1. Prone platform including polycarbonate centrepiece with aperture, 
polystyrene head and body supports, and polystyrene wedge to support 
contralateral breast 
 
Figure 2.  Distributions of patients by a) cup size and b) whole-breast clinical-target 
volume 
 
Figure 3a-e.  Box and whiskers plots displaying normal tissue dosimetry a) Heart-
NTDmean b) LAD-NTDmean c) LADmax (figures 3a-c include left-breast-affected 
women only, n=30) d) Ipsilateral-lung NTDmean (n=65) e) Chest-wall V50Gy  
(n=65). Black dots= outliers (numbers represent trial-numbers) 
 
Figure 4.  Relationship of breast-tissue (cyan-outline), heart (pink-outline), and left-
anterior-descending coronary-artery (red-outline with cyan-bullseye) to 
chest-wall for: i) woman of cup-size B and ii) woman of cup-size F a) supine 
and b) prone 
 
Figure 5.  Mean difference in cardiac variables (supine minus prone) expressed by 
whole-breast clinical-target volume tertile for a) WBI and b) PBI. (Negative 
values= benefit of prone position) 
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Figure 1.  
 
 
 
 
 
 
 
 
Prone breast dosimetry    Kirby page 22
Figure 2.  
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Figure 3.  
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Figure 4.  
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Figure 5. 
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